Blueprint
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): April 9,
2018
WOUND
MANAGEMENT TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Texas
|
|
000-11808
|
|
59-2219994
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
1200
Summit Avenue, Suite 414
Fort
Worth, Texas
|
|
76102
|
(Address
of principal executive offices)
|
|
(zip
code)
|
Registrant’s telephone number, including area code:
(817)-529-2300
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective as of
April 11, 2018, Wound Management
Technologies, Inc. (the “Company”) has appointed
Michael D. McNeil, 53, to serve as the Company’s new Chief
Financial Officer. The
Company’s previous Chief Financial Officer, J. Michael
Carmena, was appointed to serve as the Company’s Chief
Executive Officer in February 2018.
Prior to joining the Company, Mr. McNeil served
as Controller for Smith and
Nephew’s U.S. Advanced Wound Management Division from 2012 to
2018. Mr. McNeil previously served as Controller and Assistant
Controller with Healthpoint Biotherapeutics from 1999 to 2012.
Prior to his employment at Healthpoint, Mr. McNeil held several
finance and internal audit positions with Burlington Resources,
Snyder Oil Corporation, and Union Pacific Corporation. Mr. McNeil
earned his Bachelor of Science in Business Administration from the
University of Nebraska and is a Texas certified public
accountant.
The
Board of Directors of the Company believes that Mr. McNeil’s
strong financial background and medical industry experience will
enhance the Company’s sales and operations teams as well as
its finance and accounting functions.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
WOUND
MANAGEMENT TECHNOLOGIES, INC.
|
|
|
|
|
|
Date:
April 16, 2018 |
By:
|
/s/ Michael Carmena
|
|
|
|
Name:
Michael Carmena |
|
|
|
Title:Chief
Executive Officer |
|